FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Amyloidosis | Cardiology | Cardiomyopathy | Food and Drug Administration (FDA) | Heart | Heart Disease | Pharmaceuticals | Rare Diseases